3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Lymphoid
2
Dermatologic
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Endocrine
1
CNS
1
Conditions
Differentiated Thyroid Cancer
1
Interventions
Everolimus
10
lanreotide
4
Capecitabine
4
pasireotide
3
lutetium Lu 177 dotatate
3
lenvatinib
3
fosbretabulin
3
Temozolomide
3
Sorafenib
3
Paclitaxel
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
Erlotinib Hydrochloride
3
Doxorubicin
3
trifluridine tipiracil drug combination
2
surufatinib
2
pembrolizumab
2
pegfilgrastim
2
gallium Ga 68 dotatate
2
durvalumab
2
dactolisib
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Sunitinib
2
Rosiglitazone
2
Radiotherapy
2
Panobinostat
2
Mitotane
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
AZD 6244
×
Endocrine
×
Clear all
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts